首页> 美国卫生研究院文献>BMC Cancer >Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

【2h】

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

机译：帕妥珠单抗和曲妥珠单抗加艾瑞布林或纳布-紫杉醇治疗的人表皮生长因子受体2阳性晚期乳腺癌中绝对淋巴细胞计数对无进展生存的预测影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 BMC Cancer
作者
Kazuhiro Araki; Yoshinori Ito; Ippei Fukada; Kokoro Kobayashi; Yoshimasa Miyagawa; Michiko Imamura; Ayako Kira; Yuichi Takatsuka; Chiyomi Egawa; Hirofumi Suwa; Shinji Ohno; Yasuo Miyoshi;
展开▼
作者单位

展开▼
年(卷),期 2018(18),-1
年度 2018
页码 982
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Absolute lymphocyte counts Predictive biomarker Pertuzumab Trastuzumab HER2-positive ABC Host immunity;

机译：绝对淋巴细胞计数;预测性生物标志物;帕妥珠单抗;曲妥珠单抗;HER2阳性ABC;宿主免疫;

相似文献

外文文献
中文文献
专利

1. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel [J] . Kazuhiro Araki, Yoshinori Ito, Ippei Fukada, BMC Cancer . 2018,第1期

机译：绝对淋巴细胞计数对使用培妥珠单抗和曲妥珠单抗加艾瑞布林或纳布紫杉醇治疗的人表皮生长因子受体2阳性晚期乳腺癌无进展生存的预测影响
2. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [J] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, Breast cancer . 2019,第4期

机译：曲妥珠单抗氨丹宁在先前使用曲妥珠单抗和帕妥珠单抗联合治疗以及仅在日本人群中联合曲妥珠单抗治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
3. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017) [J] . Perez Journal of Clinical Oncology . 2017,第20期

机译：曲妥珠单抗与Pertuzumab与retsuzumab和紫罗兰人为人体表皮生长因子受体2阳性，晚期乳腺癌的紫罗兰毒素：III期玛丽安学习的主要结果（Vol 35，PG 141,2017）
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, -1

机译：曲妥珠单抗氨丹宁在仅使用过曲妥珠单抗和帕妥珠单抗联合曲妥珠单抗治疗且仅在日本人群中治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

著录项

相似文献

相关主题

期刊订阅